Novakand Pharma Balance Sheet Health
Financial Health criteria checks 4/6
Novakand Pharma has a total shareholder equity of SEK43.1M and total debt of SEK0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are SEK46.7M and SEK3.6M respectively.
Key information
0%
Debt to equity ratio
SEK 0
Debt
| Interest coverage ratio | n/a |
| Cash | SEK 27.60m |
| Equity | SEK 43.12m |
| Total liabilities | SEK 3.58m |
| Total assets | SEK 46.70m |
Recent financial health updates
Companies Like Kancera (STO:KAN) Are In A Position To Invest In Growth
Aug 13
We Think Kancera (STO:KAN) Needs To Drive Business Growth Carefully
Dec 06Is Kancera (STO:KAN) In A Good Position To Deliver On Growth Plans?
Jul 19Companies Like Kancera (STO:KAN) Are In A Position To Invest In Growth
Mar 08We Think Kancera (STO:KAN) Can Afford To Drive Business Growth
Jun 29We're Hopeful That Kancera (STO:KAN) Will Use Its Cash Wisely
Mar 08Recent updates
Companies Like Kancera (STO:KAN) Are In A Position To Invest In Growth
Aug 13We Think Kancera (STO:KAN) Needs To Drive Business Growth Carefully
Dec 06Is Kancera (STO:KAN) In A Good Position To Deliver On Growth Plans?
Jul 19Companies Like Kancera (STO:KAN) Are In A Position To Invest In Growth
Mar 08We Think Kancera (STO:KAN) Can Afford To Drive Business Growth
Jun 29We're Hopeful That Kancera (STO:KAN) Will Use Its Cash Wisely
Mar 08Here's Why We're Watching Kancera's (STO:KAN) Cash Burn Situation
Aug 02We're Not Very Worried About Kancera's (STO:KAN) Cash Burn Rate
Apr 06Here's Why We're Not Too Worried About Kancera's (STO:KAN) Cash Burn Situation
Dec 21Financial Position Analysis
Short Term Liabilities: NOVKAN's short term assets (SEK28.7M) exceed its short term liabilities (SEK3.6M).
Long Term Liabilities: NOVKAN has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: NOVKAN is debt free.
Reducing Debt: NOVKAN had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NOVKAN has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: NOVKAN has less than a year of cash runway if free cash flow continues to reduce at historical rates of 7.4% each year
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/30 16:24 |
| End of Day Share Price | 2025/10/30 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Novakand Pharma AB (publ) is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Johan Stromqvist | ABG Sundal Collier Sponsored |
| Martin Wahlstrom | Redeye |
| Filip Lindkvist | Redeye |